Laura Vergani joins the international biopharmaceuticals group after working with big names including Walgreens Boots Alliance, Barclays, and Standard & Poor’s.
MSD and Curon have announced that they have entered into a definitive agreement under which MSD has agreed to acquire CN201, a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases.
Otsuka Pharmaceuticals is collaborating with Health Innovation Oxford HIN to evaluate the implementation and integration of a new digital therapeutic (DTx), CARE for MDD, intended to support the treatment of major depressive disorder (MDD).
Specialising in pharmaceuticals, the site offers a variety of services including mixing and blending, storage, transportation, and quality-assured repackaging of active ingredients.
Within the new group of companies, Konapharma now complements the services of packaging company Allpack and Rhenochem, a family-owned company with decades of extensive experience and expertise in the global pharmaceutical industry.
The agreement spans the Republic of South Africa and members of the GCC alliance, including Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates.
Johnson & Johnson Innovative Medicine have announced its strengthened commitment in Italy, with a projected investment of 580 million euros over the next five years, of which €125 million will support an increase in production capacity.
Cycle Pharmaceuticals a rapidly growing pharmaceutical company focused on treatments for the underserved rare disease patient community, have confirmed that it made a proposal to the Board of Directors of Vanda Pharmaceuticals, Inc.
